WeWork's tech head explains why the office provider is buying a building access app used by top landlords

WeWork's chief technology officer said Waltz, which includes 30 employees, will help the office provider get rid of keycards.

June 26, 2019   |   View Online »

WeWork's tech head explains why the office provider is buying a building access app used by top landlords Meghan Morris | WeWork's chief technology officer said Waltz, which includes 30 employees, will help the office provider get rid of keycards. Read More »

Frugal investor Vanguard is reportedly eyeing a push into private equity. It could cause a 'cultural backlash' between haves and have-nots. Meghan Morris,Casey Sullivan | Vanguard tried a similar private equity approach in 2001 that ultimately failed because of fundraising issues after the dot-com crash. Read More »

JPMorgan warns of a major risk that could catch cash-strapped stock investors off guard — and reveals the 'one scenario' that might keep the rally afloat Christopher Competiello | Failure to validate market expectations could spell the end of the equity bull market as investors run low on dry powder. Read More »

Most people think real estate is a safe bet, but 1 key indicator looks like we're in for another Great Recession Alex Nicoll | While most signs show a strong market, Joe Azelby is concerned by investor portfolios that include an increasing percentage of value-add real estate. Read More »

Goldman Sachs is making renewable energy a big priority based on its hiring strategy. It's a sign that its idea incubator is working. Callum Burroughs,Dakin Campbell | The bank is hiring for a VP of operations whose responsibilities will include investment strategies in the "green/renewable energy industry." Read More »

A former star Goldman Sachs pharma analyst just made her first deal with AbbVie's $63 billion bid for Botox-maker Allergan. Meet the bankers involved in the megamerger. Lydia Ramsey | Bankers from Morgan Stanley and PJT Partners advised AbbVie on the takeover, while JPMorgan advised Allergan. Read More »

JPMORGAN: Investors have a 3-item wish list, but getting all of them will be impossible. Here's how they can outsmart a complex market trap. Marley Jay | JPMorgan Asset Management says investors want an end to the trade war, better global growth, and lower interest rates. But they can't have all three. Read More »

AbbVie's $63 billion megadeal for Botox maker Allergan is the pharma industry's latest bet that bigger is better. But the deal is already facing big questions. Emma Court | Wall Street is already questioning whether the merger makes sense. "Two turkeys don't make an eagle," Piper Jaffray's analyst team said. Read More »

AbbVie said that its $63 billion deal for Allergan has at least $2 billion in 'synergies.' That should make employees nervous. Clarrie Feinstein | Around half of the cost cuts are likely to come from research and development, AbbVie said. The company is also targeting sales and marketing. Read More »

This forgotten investigation into Microsoft, 10 years before the antitrust trial, let it get away with tactics that sealed its tech dominance, according to a key player Troy Wolverton | A decade before the antitrust trial, the government missed a chance to rein in Microsoft, economist Rick Warren-Boulton said. Read More »

Share This Email    Read Business Insider On The Go

Email sent to: ipat39@gmail.com Manage your email preferences   |   Unsubscribe Terms of Service   |   Privacy Policy Business Insider. 150 Fifth Ave, New York, NY 10011